Zacks Analyst Blog Highlights: FedEx Corp., Smith & Nephew, Stryker and Zimmer.

CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day, the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: FedEx Corp. (NYSE:FDX), Smith & Nephew (NYSE:SNN), Stryker (NYSE:SYK) and Zimmer (NYSE:ZMH).

See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673.

Here are highlights from Tuesday's Analyst Blog:

Air Transport Deal for FDX

Today, FedEx Corp. (NYSE:FDX), and the U.S. Postal Service announced a new agreement for domestic air transport of mail through 2013 that replaces a previous contract entered into in 2001. Under the agreement, expected to generate about $8 billion in revenue over the life of the contract, FedEx will continue to fly over 4 million pounds of U.S. mail every business day.

The stock is down $1.85, or 1.8%, to $102.86 in morning trading. We continue our Hold recommendation on FDX.

Smith & Nephew Confesses

Yesterday, Smith & Nephew (NYSE:SNN) indicated that it may have been one of its independent representative's emails that triggered the Department of Justice investigation into possible orthopedic industry anti-trust activities. The company conducted an internal investigation after receiving the DOJ subpoena and discovered that the representative sent an email in October 2005 to competitors. The email suggested the competitors coordinate their contract proposals with a hospital. The email was not acted upon, and upon its internal findings, SNN severed its business relationship with the representative.

Assuming this is the only event that triggered the June 2006 DOJ investigation, the SNN revelation could resolve the matter quickly. Importantly, the news removes an overhang over other orthopedic company stocks, including Stryker (NYSE:SYK) and Zimmer (NYSE:ZMH).

See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.